{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:30:20Z","timestamp":1771824620712,"version":"3.50.1"},"reference-count":77,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.bmc.2020.115466","type":"journal-article","created":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T11:32:24Z","timestamp":1585395144000},"page":"115466","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules"],"prefix":"10.1016","volume":"28","author":[{"given":"Krishnappa","family":"Ramya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramalingam","family":"Suresh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Honnavalli Yogish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.R. Prashantha","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.B. Sridhara","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2020.115466_b0005","article-title":"report on cardiovascular diseases","author":"WHO","year":"2017","journal-title":"World Health Organization"},{"issue":"8","key":"10.1016\/j.bmc.2020.115466_b0010","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.cellsig.2012.04.003","article-title":"How well do aliskiren's purported mechanisms track its effects on cardiovascular and renal disorders?","volume":"24","author":"Jagadeesh","year":"2012","journal-title":"Cell Signal"},{"issue":"6","key":"10.1016\/j.bmc.2020.115466_b0015","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.bmc.2020.115466_b0020","series-title":"Pathophysiology and Pharmacotherapy of Cardiovascular Disease, Chapter 36, Drugs targeting RAS in the treatment of Hypertension and other Cardiovascular diseases","first-page":"751","author":"Jagadeesh","year":"2015"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario","year":"2006","journal-title":"Am J Cardiol"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1084\/jem.59.3.347","article-title":"Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia","volume":"59","author":"Goldblatt","year":"1934","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0035","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1016\/j.cellsig.2014.06.011","article-title":"A century old renin\u2013angiotensin system still grows with endless possibilities: AT1 receptor signaling cascades in cardiovascular physiopathology","volume":"26","author":"Balakumar","year":"2014","journal-title":"Cellular Signaling"},{"issue":"11","key":"10.1016\/j.bmc.2020.115466_b0040","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1172\/JCI0214276","article-title":"Pivotal role of the renin\/prorenin receptor in angiotensin II production and cellular responses to renin","volume":"09","author":"Nguyen","year":"2002","journal-title":"J Clin Investig"},{"issue":"5","key":"10.1016\/j.bmc.2020.115466_b0045","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/FJC.0b013e3181f21576","article-title":"Cardiovascular and renal pathologic implications of prorenin, renin, and the (pro) renin receptor: promising young players from the old renin-angiotensin-aldosterone system","volume":"56","author":"Balakumar","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0050","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1681\/ASN.2004100874","article-title":"Renin inhibition: what are the therapeutic opportunities?","volume":"16","author":"Fisher","year":"2005","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0055","first-page":"11","volume":"1","author":"Navajyothi","year":"2015","journal-title":"Early diagnosis of hypertension: Research and Reviews: Journal of Hospital and Clinical Pharmacy"},{"issue":"5","key":"10.1016\/j.bmc.2020.115466_b0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacc.2007.10.027","article-title":"Renin inhibition in hypertension","volume":"51","author":"Gradman","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.bmc.2020.115466_b0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41569-019-0244-8","article-title":"Counter-regulatory renin\u2013angiotensin system in cardiovascular disease","volume":"17","author":"Ocaranza","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"Part A","key":"10.1016\/j.bmc.2020.115466_b0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.07.003","article-title":"Renin-angiotensin-aldosterone: an inclusive, an invigorative, an interactive and an interminable system","volume":"125","author":"Balakumar","year":"2017","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0075","first-page":"1","article-title":"COVID-19 and the cardiovascular system","volume":"5","author":"Zheng","year":"2020","journal-title":"Nat Rev Cardiol"},{"issue":"8","key":"10.1016\/j.bmc.2020.115466_b0080","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1001\/jama.2020.0757","article-title":"Coronavirus infections\u2014more than just the common cold","volume":"323","author":"Paules","year":"2020","journal-title":"J Am Medical Associat"},{"issue":"20","key":"10.1016\/j.bmc.2020.115466_b0085","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1021\/bi00744a013","article-title":"Competitive inhibitors of renin","volume":"12","author":"Poulsen","year":"1973","journal-title":"Biochemistry"},{"issue":"4896","key":"10.1016\/j.bmc.2020.115466_b0090","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1126\/science.2493678","article-title":"Structure of recombinant human renin, a target for cardiovascular-active drugs, at 2.5A resolution","volume":"243","author":"Sielecki","year":"1989","journal-title":"Science"},{"issue":"4022","key":"10.1016\/j.bmc.2020.115466_b0095","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.175.4022.656","article-title":"Inhibition of the renin-angiotensinogen reaction by pepstatin","volume":"175","author":"Gross","year":"1972","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0100","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1084\/jem.106.3.439","article-title":"The preparation, purification, and amino acid sequence of a polypeptide renin substrate","volume":"106","author":"Skeggs","year":"1957","journal-title":"J Exp Med"},{"issue":"17","key":"10.1016\/j.bmc.2020.115466_b0105","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1021\/bi00688a024","article-title":"Competitive inhibitors of renin Inhibitors effective at physiological pH","volume":"14","author":"Burton","year":"1975","journal-title":"Biochemistry"},{"issue":"15","key":"10.1016\/j.bmc.2020.115466_b0110","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1021\/bi00712a005","article-title":"Renin Inhibition by proteins and peptides","volume":"13","author":"Workman","year":"1974","journal-title":"Biochemistry"},{"issue":"12","key":"10.1016\/j.bmc.2020.115466_b0115","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1021\/jm00246a003","article-title":"Synthesis of lysophosphatidylethanolamine analogs that inhibit renin activity","volume":"18","author":"Turcotte","year":"1975","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0120","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1021\/jm00364a019","article-title":"Inhibition of renin by angiotensinogen peptide fragments containing the hydroxy amino acid residue 5-amino-3-hydroxy-7-methyloctanoic acid","volume":"26","author":"Johnson","year":"1983","journal-title":"J Med Chem"},{"issue":"12","key":"10.1016\/j.bmc.2020.115466_b0125","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1021\/jm00150a007","article-title":"Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analog inhibitors containing a novel analog of statine","volume":"28","author":"Boger","year":"1985","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0130","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1021\/jm00392a016","article-title":"Fluoro ketone containing peptides as inhibitors of human renin","volume":"30","author":"Fearon","year":"1987","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0135","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1021\/jm00114a026","article-title":"Peptide to glycopeptide: glycosylated oligopeptide renin inhibitors with attenuated in vivo clearance properties","volume":"34","author":"Fisher","year":"1991","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0140","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1021\/jm00381a001","article-title":"Pepstatin-derived inhibitors of aspartic proteinases. A close look at an apparent transition-state analog inhibitor","volume":"28","author":"Rich","year":"1985","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0145","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1021\/jm00376a023","article-title":"Inhibition of renin by substrate analog inhibitors containing the olefinic amino acid 5 (S)-amino-7-methyl-3 (E)-octenoic acid","volume":"27","author":"Johnson","year":"1984","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0150","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1021\/jm00117a027","article-title":"Synthesis and biological activity of some transition-state inhibitors of human renin","volume":"31","author":"Buehlmayer","year":"1988","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2020.115466_b0155","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/jm00056a006","volume":"36","author":"Rosenberg","year":"1993","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmc.2020.115466_b0160","doi-asserted-by":"crossref","first-page":"3755","DOI":"10.1021\/jm00099a004","article-title":"Highly potent, orally active diester macrocyclic human renin inhibitors","volume":"35","author":"Weber","year":"1992","journal-title":"J Med Chem"},{"issue":"19","key":"10.1016\/j.bmc.2020.115466_b0165","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1021\/jm00071a009","article-title":"Renin inhibitors containing a pyridyl amino diol derived C-terminus","volume":"36","author":"Heitsch","year":"1993","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd2796","article-title":"The influence of lead discovery strategies on the properties of drug candidates","volume":"8","author":"Keser\u00fc","year":"2009","journal-title":"Nat Rev Drug Discovery"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0175","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1074-5521(99)89004-8","article-title":"Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?","volume":"6","author":"Oefner","year":"1999","journal-title":"Chem Biol"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0180","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0960-894X(99)00196-1","article-title":"Piperidine-renin inhibitors compounds with improved physicochemical properties","volume":"9","author":"G\u00fcller","year":"1999","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0185","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1016\/j.bmcl.2006.01.084","article-title":"Ketopiperazine-based renin inhibitors: optimization of the \u201cC\u201d ring","volume":"16","author":"Holsworth","year":"2006","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0190","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1271\/bbb.60213","article-title":"Kinetics of renin inhibition by sodium houttuyfonate analogs","volume":"70","author":"Yuan","year":"2006","journal-title":"Biosci Biotechnol Biochem"},{"issue":"21","key":"10.1016\/j.bmc.2020.115466_b0195","doi-asserted-by":"crossref","first-page":"7490","DOI":"10.1021\/jm901885s","article-title":"Direct renin inhibitors as a new therapy for hypertension","volume":"53","author":"Webb","year":"2010","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.bmc.2020.115466_b0200","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0006-291X(03)01451-7","article-title":"Structure-based design of aliskiren, a novel orally effective renin inhibitor","volume":"308","author":"Wood","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.bmc.2020.115466_b0205","first-page":"105","article-title":"Case history on Tekturna\/Rasilez(Aliskiren), a highly efficacious direct oral renin inhibitor as a new therapy for hypertension","volume":"44","author":"Maibaum","year":"2009","journal-title":"Annu Rep Med Chem"},{"issue":"13","key":"10.1016\/j.bmc.2020.115466_b0210","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1016\/j.bmcl.2007.04.052","article-title":"Discovery of 6-ethyl-2, 4-diaminopyrimidine-based small molecule renin inhibitors","volume":"17","author":"Holsworth","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmc.2020.115466_b0215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.18553\/jmcp.2007.13.s8-b.21","article-title":"Direct renin inhibition: focus on aliskiren","volume":"13","author":"Pool","year":"2007","journal-title":"J Managed Care Pharmacy"},{"issue":"12","key":"10.1016\/j.bmc.2020.115466_b0220","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1021\/jm900022f","article-title":"Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors","volume":"52","author":"Bezen\u00e7on","year":"2009","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2020.115466_b0225","doi-asserted-by":"crossref","first-page":"4818","DOI":"10.1021\/jm070314y","article-title":"Novel 2, 7-dialkyl-substituted5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin","volume":"50","author":"G\u00f6schke","year":"2007","journal-title":"J Med Chem"},{"issue":"20","key":"10.1016\/j.bmc.2020.115466_b0230","doi-asserted-by":"crossref","first-page":"4832","DOI":"10.1021\/jm070316i","article-title":"Structural modification of the P2 \u2018position of 2, 7-dialkyl-substituted 5 (S)-amino-4 (S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets","volume":"50","author":"Maibaum","year":"2007","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmc.2020.115466_b0235","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2550","article-title":"Aliskiren: the first renin inhibitor for clinical treatment","volume":"7","author":"Jensen","year":"2008","journal-title":"Nat Rev Drug Discovery"},{"issue":"24","key":"10.1016\/j.bmc.2020.115466_b0240","doi-asserted-by":"crossref","first-page":"7677","DOI":"10.1016\/j.bmcl.2012.09.103","article-title":"Design and discovery of new (3S, 5R)-5-[4-(2-chlorophenyl)-2, 2-dimethyl-5-oxopiperazin-1-yl] piperidine-3-carboxamides as potent renin inhibitors","volume":"22","author":"Mori","year":"2012","journal-title":"Bioorg Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0245","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1021\/ml300168e","article-title":"Discovery of DS-8108b, a novel orally bioavailable renin inhibitor","volume":"3","author":"Nakamura","year":"2012","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"10.1016\/j.bmc.2020.115466_b0250","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1517\/17460441.2013.791279","article-title":"Recent progress on the discovery of non-peptidic direct renin inhibitors for the clinical management of hypertension","volume":"8","author":"Yokokawa","year":"2013","journal-title":"Expert Opin Drug Discov"},{"issue":"6","key":"10.1016\/j.bmc.2020.115466_b0255","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1021\/jm3017078","article-title":"The discovery of novel potent trans-3, 4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches","volume":"56","author":"Lorthiois","year":"2013","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.bmc.2020.115466_b0260","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1016\/j.bmcl.2010.02.036","article-title":"Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension","volume":"20","author":"Chen","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0265","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1021\/acsmedchemlett.6b00251","article-title":"Discovery of TAK-272: a novel, potent, and orally active renin inhibitor","volume":"7","author":"Imaeda","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"8","key":"10.1016\/j.bmc.2020.115466_b0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0202176","article-title":"TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model","volume":"13","author":"Hara","year":"2018","journal-title":"PLoS ONE"},{"issue":"21","key":"10.1016\/j.bmc.2020.115466_b0275","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1016\/j.bmcl.2010.08.092","article-title":"Discovery and optimization of a new class of potent and non-chiral indole-3-carboxamide-based renin inhibitors","volume":"20","author":"Scheiper","year":"2010","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0280","first-page":"17","article-title":"Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circulation","volume":"1","author":"McMurray","year":"2008","journal-title":"Heart Failure."},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2174\/187152510790796174","article-title":"Aliskiren: a new drug for an old problem","volume":"8","author":"Barrios","year":"2010","journal-title":"Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents)"},{"issue":"2","key":"10.1016\/j.bmc.2020.115466_b0290","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/0975-7406.80764","article-title":"Aliskiren: an orally active renin inhibitor","volume":"3","author":"Wal","year":"2011","journal-title":"J Pharm Bioallied Sci"},{"issue":"5","key":"10.1016\/j.bmc.2020.115466_b0295","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/2040622313495288","article-title":"Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials","volume":"4","author":"\u015een","year":"2013","journal-title":"Therapeutic Adv Chronic Dis"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0300","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1161\/HYPERTENSIONAHA.108.111120","article-title":"Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes","volume":"52","author":"Imanishi","year":"2008","journal-title":"Hypertension"},{"issue":"3","key":"10.1016\/j.bmc.2020.115466_b0305","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1152\/ajprenal.00373.2009","article-title":"Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat","volume":"298","author":"Whaley-Connell","year":"2009","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"11","key":"10.1016\/j.bmc.2020.115466_b0310","doi-asserted-by":"crossref","first-page":"5643","DOI":"10.1210\/en.2008-0070","article-title":"Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat","volume":"149","author":"Habibi","year":"2008","journal-title":"Endocrinology"},{"issue":"4","key":"10.1016\/j.bmc.2020.115466_b0315","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/CIRCULATIONAHA.108.826214","article-title":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy","volume":"119","author":"Solomon","year":"2009","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.bmc.2020.115466_b0320","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015052","article-title":"Effects of aliskiren on stroke in rats expressing human renin and angiotensinogen genes","volume":"5","author":"Schmerbach","year":"2010","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.bmc.2020.115466_b0325","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1007\/s11064-016-1944-7","article-title":"Protective effect of aliskiren in experimental ischemic stroke: up-regulated p-PI3K, p-AKT, Bcl-2 expression, attenuated bax expression","volume":"41","author":"Miao","year":"2016","journal-title":"Neurochem Res"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0330","article-title":"Central application of Aliskiren, a renin inhibitor, improves outcome after experimental stroke independent of its blood pressure lowering effect","volume":"10","author":"Panahpour","year":"2019","journal-title":"Front Neurol"},{"issue":"12","key":"10.1016\/j.bmc.2020.115466_b0335","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.2337\/db08-0805","article-title":"Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis","volume":"57","author":"Singh","year":"2008","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.bmc.2020.115466_b0340","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.2165\/00003495-200767120-00008","article-title":"Aliskiren; a review of its use in the management of hypertension","volume":"67","author":"Frampton","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0345","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/ki.2009.105","article-title":"Aliskiren: a novel renoprotective agent or simply an alternative to ACE inhibitors?","volume":"76","author":"Wiggins","year":"2009","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.bmc.2020.115466_b0350","first-page":"453","article-title":"Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors","volume":"5","author":"Pimenta","year":"2009","journal-title":"Vascular Health Risk Manage"},{"issue":"25","key":"10.1016\/j.bmc.2020.115466_b0355","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1161\/CIRCULATIONAHA.108.767202","article-title":"Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans","volume":"117","author":"Fisher","year":"2008","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0360","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/eurheartj\/ehq522","article-title":"Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction","volume":"32","author":"Solomon","year":"2011","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0365","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/ejhf.408","article-title":"The Aliskiren Trial to Minimize Outcomes in Patients with Heart failure trial (ATMOSPHERE): revised statistical analysis plan and baseline characteristics","volume":"17","author":"Krum","year":"2015","journal-title":"Eur J Heart Fail"},{"issue":"23","key":"10.1016\/j.bmc.2020.115466_b0370","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.bmc.2020.115466_b0375","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2013.1954","article-title":"Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial","volume":"309","author":"Gheorghiade","year":"2013","journal-title":"J Am Med Association"},{"issue":"11","key":"10.1016\/j.bmc.2020.115466_b0380","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1001\/jama.2013.277169","article-title":"Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial","volume":"310","author":"Nicholls","year":"2013","journal-title":"J Am Med Assoc"},{"issue":"10","key":"10.1016\/j.bmc.2020.115466_b0385","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1751-7176.2010.00352.x","article-title":"Safety and tolerability of the direct renin inhibitor aliskiren: a pooled analysis of clinical experience in more than 12,000 patients with hypertension","volume":"12","author":"White","year":"2010","journal-title":"J Clin Hypertension"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620302807?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089620302807?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T01:07:04Z","timestamp":1760836024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089620302807"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0968089620302807"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115466","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decades-old renin inhibitors are still struggling to find a niche in antihypertensive therapy. A fleeting look at the old and the promising new molecules","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2020.115466","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115466"}}